Table of Contents
STUDY GOALS AND OBJECTIVES
This report HLC142A Therapies and Diagnostics for Uterine Cancer provides an overview of the current and potential global market for uterine cancer, treatments, screening and testing technologies. The report provides comprehensive information on uterine cancer, highlighting treatment guidelines. It identifies and analyzes the key trends driving the global uterine cancer therapeutics market. The key objective is to present a comprehensive analysis of current uterine cancer technology and the utilization of the various therapeutic, screening and diagnostic modalities. The report’s focus is on uterine disorders, current treatment strategies and drugs, chemotherapy and other treatment modalities and testing and screening methods. Important trends in the field, research, new developments and sales forecasts by treatment and screening categories from 2013 through 2018 are provided. Issues and trends addressed in this report are based on information from industry sources, regulatory and healthcare policies, demographics and other factors that directly affect the uterine cancer market.
It also focuses on the treatment usage patterns in the global uterine cancer therapeutics market, competitive landscape, and the emerging players and pipeline products. The report also details opportunities for future players.
REASONS FOR DOING THIS STUDY
This study was conducted to provide detailed information on testing and treatment options for uterine disorders and cancer. There is an increasing need for new and innovative technologies. This industry is experiencing tremendous growth. Many diseases discussed in this report are global issues and a need exists for newer diagnostic and treatment strategies. This study looks at most types of diagnostic and treatment strategies for the clinical management of endometrial disorders and related cancers.
This BCC market research report will increase the reader’s awareness of current and emerging drugs and technologies for uterine cancers, therapeutics, chemotherapy and surgical therapy.
This report is a detailed study on the global uterine cancer market, with key statistics and analysis of current drugs and screening and diagnostic technologies, latest trends, market structure, market size, key drug segments and trends in technology. This study contributes to the areas of market growth in uterine cancer prevention and treatment strategies from the point of view of manufacturers, product suppliers, healthcare providers, and consumers of uterine cancer products and services. This study will be largely of interest to the pharmaceutical and biotechnology industries, as well as clinics, hospitals and research institutes. This report may also prove crucial for investment firms in the relative sector. This report discusses tests currently being used for uterine disorders, cancer diagnosis and prognosis, new developments, spending trends and revenue prospects for these technologies. The report provides market data for 2012 to 2018 and also covers commercial prospects, uterine cancer diagnostic tests in use and future growth.
SCOPE OF THE STUDY
The scope of this study is diagnostic test and therapeutic markets for uterine cancers. Screening tests are included as discussion only, as new studies have reflected that Pap smears, CT scans and ultrasound could be used as screening aids for uterine cancer. The exact usage for these tests for uterine cancer is still under research; therefore, sales numbers and revenue forecasts from this segment are not included in the final market summary. The focus of this report is on diagnostic tests and therapeutics for uterine cancer, including surgery and diagnostic methods (e.g., hysteroscopy and endometrial biopsy) that are currently in use. The report also includes discussions on the current technologies, new technologies, incidence, market projections and market share, along with the latest trends and new developments.
Both primary and secondary research methodologies were used in preparing this report. Secondary sources include books, newspapers, trade journals, white papers, industry portals, government agencies, trade associations, industry news and developments, and paid and free databases. The base year of the report is 2012, with forecast data provided through 2018. Historical, base year and forecast data are provided for each market segment of this report. The report provides a comprehensive review of uterine cancer, incidence and development of the disease, drugs currently being used and diagnostic technologies. The report also reviews technological developments, product innovations/introductions and recent strategic industry activity of major players across various product categories. Growth rates, global incidence and projections are determined through a compilation of data, including past trends, future trends, demographics, incidence, mortality, products in R&D and current product growth. Forecasts and projections were based on estimates such as the current trends, potential users, mergers and acquisitions, and market trends.
A comprehensive and exhaustive search of the literature on uterine cancer and disorders, products, global incidence and drug development was conducted. These secondary sources included scientific journals and articles, textbooks, press releases, marketing literature, other product/promotional literature, annual reports, security analyst reports and other publications. A patent search and analysis were also conducted. Some informal interviews were also conducted with experts and personnel in this area at biotech and pharmaceutical companies. Other resources included academics, technology and consulting companies.
Many companies within the industry were surveyed to obtain data for this study. Included were manufacturers and end users of products such as the pharmaceutical and biotechnical industries and research institutes. Data were gathered from various industry sources. BCC spoke with officials within academia, industry and the medical community, and consulted newsletters, company literature, product literature and a host of technical articles, journals, indexes and abstracts. Exhaustive investigations of databases by key terminology were completed. In addition, data were compiled from current financial, trade and government sources.
ABOUT THE AUTHOR
Usha Nagavarapu is an experienced pharmaceutical professional with scientific and business development experience. She has managed preclinical discovery programs from target identification, including Investigational New Drug (IND) enabling studies, and assisted out-licensing and portfolio development activities. Her strong focus areas include oncology, dermatology and cardiovascular diseases. She has extensive experience working with early start-ups to fulfill operational obligations while minimizing overall operational cost and burden.
This report provides:
• An overview of the global market for diagnostics and therapies for uterine cancer
• Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018
• A breakdown of the markets by diagnostics and screening, surgery, radiation therapy, and drug therapy
• Discussion of uterine cancer biology
• Delineation of drugs approved and in the pipeline to treat the disease, including chemotherapeutic and immunotherapeutic
• Evaluation of the patent landscape
• Comprehensive profiles of key companies.
Get Industry Insights. Simply.
Talk to Veronica
+1 718 514 2762
PharmaPoint: Colorectal Cancer - Global Drug Forecast and Market Analysis to 2025 Summary Colorectal Cancer (CRC) Market, considering the sales of both branded treatments and generic chemotherapy, is expected ...
Use this report to: - Analyze the global prostate cancer market, with important statistics and analysis on existing drugs, and diagnostic technologies. - Receive information on regulatory environment, ...
Complete report $9,800. DataPack (test volumes, sales forecasts, supplier shares) $6,400. Highlights Comprehensive 620-page analysis of the US tumor marker testing market.Major issues pertaining to the ...